Novartis Withdraws EU Approval for Anoro Breezhaler COPD Treatment
Commercial Reasons for EU Approval Withdrawal
The European Union Executive Committee withdrew the marketing authorization for Anoro Breezhaler at the request of Novartis Europharm on August 30, 2026. The reason provided by Novartis is a commercial decision to permanently discontinue the product, not due to safety or efficacy issues. Therefore, interpreting this action as a clinical failure or forced withdrawal by a regulatory authority is inaccurate. Since this is not a separate acquisition or licensing transaction, no upfront payment, milestones, or royalties will be incurred.
Approval History and Drug Characteristics
Anoro Breezhaler is a long-acting muscarinic antagonist (LAMA) containing glycopyrronium bromide at 44 micrograms, administered once daily. It blocks the muscarinic action of acetylcholine to inhibit bronchoconstriction and was used as a maintenance bronchodilator for symptom relief in adult patients with chronic obstructive pulmonary disease (COPD). The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on June 21, 2012, and the EU marketing authorization was granted on September 28, 2012. The product status has transitioned from Marketed to Withdrawal, and this is unrelated to the U.S. FDA advisory committee (AdComm) process.
Patients and Competitive Landscape
The product withdrawal does not signify the extinction of the glycopyrronium ingredient itself. European physicians can choose other LAMAs with the same active ingredient, such as Seebri Breezhaler, along with Boehringer Ingelheim's Spiriva (tiotropium), GSK's Incruse Ellipta (umeclidinium), and Eclira Geniair (aclidinium). For patients with persistent symptoms, LABA/LAMA combinations such as Ultibro Breezhaler (indacaterol/glycopyrronium), Anoro Ellipta (umeclidinium/vilanterol), and Spiolto Respimat (tiotropium/olodaterol) are competitive. With multiple treatment options available, the impact on patient access and the supply chain is limited.
Market and Portfolio Implications
According to AstraZeneca's 2024 annual report, the global COPD drug market is valued at USD 17.1 billion annually. In this market, dual bronchodilators and triple therapies including inhaled corticosteroids (ICS) are gaining greater share than single LAMAs. Anoro is not included in Novartis's top 20 products for 2025, so its impact on the group's USD 54.532 billion revenue is non-core. This withdrawal aligns more with brand rationalization and portfolio optimization for a mature respiratory portfolio than with any negative regulatory judgment on the glycopyrronium mechanism.
From an investor perspective, this event is a portfolio rationalization of a mature product by Novartis (NVS), not a clinical or safety risk, so the signal to overall company value is limited. Anoro was a marketed maintenance therapy for COPD approved in the EU since 2012, but the USD 17.1 billion global COPD market is shifting toward LABA/LAMA combinations and triple therapies. Competitive alternatives such as Spiriva, Incruse Ellipta, Ultibro Breezhaler, Anoro Ellipta, and Spiolto Respimat provide sufficient prescribing flexibility. For researchers, it is important to note that this withdrawal does not represent a regulatory judgment against the LAMA mechanism, including M3 muscarinic receptors, or the efficacy of glycopyrronium. For the industry, the significance lies more in brand consolidation, cost savings in manufacturing and drug safety monitoring, and long-term lifecycle management rather than short-term revenue impact.
Source: EMA (ema)
https://www.ema.europa.eu/en/medicines/human/EPAR/enurev-breezhaler